title: A new recombinant human bone morphogenetic protein-2 carrier for bone regeneration.
abstract: A gelatin sponge was formed by foaming and heat treating a gelatin solution, followed by coating the solid with poly(D,L-lactic-co-glycolic acid) to reinforce the gelatin framework. This sponge was tested for its suitability as a biodegradable porous, recombinant human bone morphogenetic protein (rhBMP)-2 carrier. Incorporation of rhBMP-2 into the sponge was closely related to its bulk density of gelatin sponge. The calcium content in the sponges, as assessed by an ectopic bone formation assay in rats, increased with the increasing sponge bulk density. Histologic and peripheral quantitative computed tomography analysis of implants in this ectopic assay system revealed cell growth throughout the carrier in 4 weeks after implantation regardless gelatin bulk density. The carrier containing rhBMP-2 maintained its three-dimensional structure after implantation; the carrier resisted collapse caused by soft tissue pressure during rapid bone formation as assessed by soft X-ray photographs. These results indicate that this newly developed sponge has excellent carrier characteristics to introduce rhBMP-2 into areas needed for bone regeneration.
authors.affiliation: Novel Pharmaceutical Laboratories, Institute for Drug Development and Research, Yamanouchi Pharmaceutical Co., Ltd. 180 Ozumi, Yaizu-shi, Shizuoka-ken 425-0072, Japan. yokota_s@yamanouchi.co.jp
authors.forename: S
authors.initials: S
authors.lastname: Yokota
authors.forename: S
authors.initials: S
authors.lastname: Sonohara
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: M
authors.initials: M
authors.lastname: Murai
authors.forename: S
authors.initials: S
authors.lastname: Shimokawa
authors.forename: R
authors.initials: R
authors.lastname: Fujimoto
authors.forename: S
authors.initials: S
authors.lastname: Fukushima
authors.forename: S
authors.initials: S
authors.lastname: Kokubo
authors.forename: K
authors.initials: K
authors.lastname: Nozaki
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: S
authors.initials: S
authors.lastname: Yokohama
authors.forename: T
authors.initials: T
authors.lastname: Sonobe
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage*; D001861:Bone Regeneration; D004337:Drug Carriers; D005780:Gelatin / Q000008:administration & dosage*; D006801:Humans; D019344:Lactic Acid / Q000008:administration & dosage; D008297:Male; D011100:Polyglycolic Acid / Q000008:administration & dosage; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage; D011161:Porifera; D051381:Rats; D011916:Rats, Inbred F344; D011994:Recombinant Proteins / Q000008:administration & dosage; D016212:Transforming Growth Factor beta
chemical_list: C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D011108:Polymers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D005780:Gelatin